Christine A Poon Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

REGN Quotes by TradingView

Christine A Poon is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 5,064 shares of REGN, which is worth approximately $3.51 Million. The most recent transaction as insider was on Oct 30, 2025, when has been sold 2,712 shares (Common Stock) at a price of $520.01 per share, resulting in proceeds of $1,410,267. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.06K
115.31% 3M change
131.66% 12M change
Total Value Held $3.51 Million

CHRISTINE A POON Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 30 2025
BUY
Exercise of conversion of derivative security
$1,410,267 $520.01 p/Share
2,712 Added 34.88%
5,064 Common Stock
Oct 29 2025
SELL
Open market or private sale
$4,256,915 $654.91 p/Share
6,500 Reduced 73.43%
2,352 Common Stock
Oct 29 2025
BUY
Exercise of conversion of derivative security
$3,380,065 $520.01 p/Share
6,500 Added 42.34%
8,852 Common Stock
Jan 02 2025
BUY
Grant, award, or other acquisition
-
166 Added 6.59%
2,352 Common Stock
Dec 20 2024
BUY
Acquisition or disposition by will or laws
-
14 Added 0.64%
2,186 Common Stock
Aug 15 2024
SELL
Open market or private sale
$12,554,630 $1158.39 p/Share
10,838 Reduced 83.31%
2,172 Common Stock
Aug 15 2024
BUY
Exercise of conversion of derivative security
$4,479,670 $413.33 p/Share
10,838 Added 45.45%
13,010 Common Stock
Jan 02 2024
BUY
Grant, award, or other acquisition
-
135 Added 5.85%
2,172 Common Stock
Aug 23 2023
SELL
Open market or private sale
$10,309,428 $839.53 p/Share
12,280 Reduced 85.77%
2,037 Common Stock
Aug 23 2023
BUY
Exercise of conversion of derivative security
$3,360,667 $273.67 p/Share
12,280 Added 46.17%
14,317 Common Stock
Jan 03 2023
BUY
Grant, award, or other acquisition
-
165 Added 7.49%
2,037 Common Stock
Aug 09 2022
SELL
Open market or private sale
$9,313,050 $620.87 p/Share
15,000 Reduced 88.9%
1,872 Common Stock
Aug 09 2022
BUY
Exercise of conversion of derivative security
$2,667,300 $177.82 p/Share
15,000 Added 47.06%
16,872 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
191 Added 9.26%
1,872 Common Stock
Aug 27 2021
SELL
Open market or private sale
$10,011,900 $667.46 p/Share
15,000 Reduced 89.92%
1,681 Common Stock
Aug 27 2021
BUY
Exercise of conversion of derivative security
$856,650 $57.11 p/Share
15,000 Added 47.35%
16,681 Common Stock
Jan 04 2021
BUY
Grant, award, or other acquisition
-
248 Added 12.86%
1,681 Common Stock
Aug 28 2020
SELL
Open market or private sale
$24,040,800 $601.02 p/Share
40,000 Reduced 96.54%
1,433 Common Stock
Aug 28 2020
BUY
Exercise of conversion of derivative security
$1,177,200 $29.43 p/Share
40,000 Added 49.12%
41,433 Common Stock

Also insider at

PRU
PRUDENTIAL FINANCIAL INC Financial Services
Director
SHW
SHERWIN WILLIAMS CO Basic Materials
Director
DBTX
Decibel Therapeutics, Inc. Healthcare
Director
NBIX
NEUROCRINE BIOSCIENCES INC Healthcare
Director
CAP

Christine A Poon

Director
Cleveland, OH

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on REGN